Publications by authors named "F van Acker"
Central nervous system (CNS) relapse in acute myeloid leukemia (AML) is rare, but prognostically extremely unfavorable and associated with very high mortality rates. Aim of our single-center study was to define risk factors for CNS relapse in patients with FLT3-mutated AML after allogeneic hematopoietic cell transplantation (HCT) and to determine the impact of pre-emptive or salvage therapy with FLT3-inhibitors (FLT3i) on occurrence of CNS relapse and overall prognosis. We analyzed 39 FLT3-mutated AML patients who were treated with intensive induction therapy and consecutively underwent HCT at our institution.
View Article and Find Full Text PDFArticle Synopsis
- MET amplification in EGFR-mutant non-small cell lung cancer (NSCLC) is a common resistance to EGFR inhibitors, and combining EGFR and MET inhibitors shows promise but has varied definitions of MET amplification.
- In a study of 43 patients with MET copy number gain, those who received the combination of EGFR and MET inhibitors had an 82% clinical benefit rate and longer progression-free survival compared to those receiving MET inhibitors alone or standard of care.
- The findings suggest that true MET amplification drives better outcomes with combination therapy, indicating a need for further research into how different types of MET copy number gain affect treatment response.
Background: First-line treatment in patients with acute myeloid leukemia (AML) unfit for intensive therapy is the combination of a hypomethylating agent (HMA) with venetoclax (VEN). However, retrospective data confirming the benefits of this regimen outside of clinical trials have shown conflicting results.
Methods: We performed a multicenter retrospective analysis of outcomes with first-line HMA-VEN versus HMA in AML patients unfit for intensive chemotherapy.